By David Jay Brown and Rebecca McClen — 2019
Ethnobotanist Terence McKenna (1946-2000) talks about psilocybin, shamanism, and the meaning of life in the April, 1992 issue of High Times.
Read on hightimes.com
CLEAR ALL
How can conscious engagement with plants, with which we’ve co-evolved since the dawn of our species, support healing in the physical, emotional and spiritual realms and help mend our separation from nature? Three brilliant herbalists/botanists, long on the cutting-edge of re-empowering the...
1
Eliot Cowan, an American-born healer, fully initiated Tsauirrikame (shaman) in the Huichol tradition, teacher, author, and founder of the alternative healing technique known as Plant Spirit Medicine, remains as a leading authority on the healing wisdom of plants.
Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.
LSD, or lysergic acid diethylamide, is a synthetic drug with potent psychedelic properties. Commonly known as acid, it was originally derived from compounds found in ergot, a fungus that grows on rye.
The latest frontier in state and local drug reform has been the loosening of legal restrictions on psilocybin—the psychoactive compound in “magic mushrooms.”
The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).
In the deep space of the psychedelic experience exists a teaching on unity principle and belonging with the earth.
As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.